Fig. 6: Antitumor efficacy of intravenously injected FP NPs in an H1975 tumor-bearing mouse model. | Nature Communications

Fig. 6: Antitumor efficacy of intravenously injected FP NPs in an H1975 tumor-bearing mouse model.

From: Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer

Fig. 6

a Schematic illustration of the experimental design. b Images of tumor and tumor weight/volume on day 19 of each group (n = 5 mice per group; one-way ANOVA followed by Tukey’s HSD post hoc test). c Tumor volume changes for each mouse in each group over 21 days of treatment (n = 5 mice per group). d The tumor volumes of mice during treatments with each group (n = 5 mice per group; two-way ANOVA followed by Tukey’s multiple comparisons post test). e The body weight of mice during treatments with each group (n = 5 mice per group; two-way ANOVA followed by Tukey’s multiple comparisons post test). Confocal images of ROS (f) and TUNEL (g) in the tumor tissues of mice after treatment with each group (n = 3 independent samples). Scale bars, 100 μm. IHC of cleaved caspase-3 (h) and H&E staining (i) in the tumor tissues after treatment with each group (n = 3 independent samples). Scale bars of cleaved caspase-3, 20 μm; Scale bars of H&E, 100 μm. Data are shown as the mean ± SD; n.s. no significance. Source data are provided as a Source Data file.

Back to article page